Key Takeaways FOLD stands out after agreeing to a $14.50-per-share buyout by BioMarin, expected to be closed in Q2 2026.FOLD's Galafold drove over 80% of sales in 9M 2025, while Pombiliti plus Opfolda showed strong initial growth.RIGL's revenues are powered by Tavalisse, with added momentum from Rezlidhia and newly acquired Gavreto.Amicus Therapeutics (FOLD) and Rigel Pharmaceuticals (RIGL) appeal to growth-focused investors as they target rare diseases, where small patient populations can still support str ...

Key Takeaways AMGN is set to report Q4 results on Feb. 3, with consensus calling for sales of $9.46B and EPS of $4.74.Amgen's newer drugs and biosimilars may lift sales, but Prolia and Xgeva face erosion after U.S. LOE.AMGN's prior-quarter one-time benefits won't be repeated, and higher R&D costs could weigh on margins.Amgen (AMGN) will report fourth-quarter and full-year 2025 results on Feb. 3 after market close. In the last reported quarter, the company's earnings beat expectations by 12.8%. The Zacks Con ...

Key Takeaways DHR beat Q4 estimates as adjusted EPS hit $2.23 and revenues rose 4.5% year over year.DHR saw broad segment growth, led by Biotechnology revenues up 9% and Diagnostics profit up 14.3%.DHR expects low single-digit core sales growth in Q1 2026 and adjusted EPS of $8.35-$8.50.Danaher Corporation’s (DHR) fourth-quarter 2025 adjusted earnings of $2.23 per share beat the Zacks Consensus Estimate of $2.22. The bottom line increased 4% year over year.Danaher reported net sales of $6.84 billion, which ...

CalciMedica, Inc. (NASDAQ:CALC) shares are down on Wednesday after the company announced the discontinuation of its Phase 2 KOURAGE clinical trial.The trial was evaluating Auxora in patients with Stage 2 or Stage 3 acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF). Data was expected in the first half of 2026.The stock is trading lower with a session volume of 23.27 million, compared to the average volume of 84.063 thousand.CalciMedica Halts KOURAGE Trial Due to Safety Conc ...

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates with a team of experienced and qualified news journalists, ensuring independent content production [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

We recently published 10 Big Names With Painful Declines. ImmunityBio Inc. (NASDAQ:IBRX) was one of the worst performers on Tuesday. ImmunityBio extended losses for a third day on Tuesday, shedding 4.19 percent to close at $5.95 apiece as investors continued to take profits after recording 14 straight days of gains last week. For the entire month of January until Thursday, January 22, ImmunityBio Inc. (NASDAQ:IBRX) has already soared by 271 percent following a flurry of positive developments, including ...

Key Takeaways Roche reported robust, placebo-adjusted weight loss up to 22.5% at 48 weeks with once-weekly CT-388.RHHBY said 47.8% on the top dose lost at least 20% body weight, while 26.1% lost over 30% by week 48.Roche said CT-388 was well tolerated, with low discontinuation rates and expected mild GI side effects.Roche Holding AG (RHHBY) announced positive top-line data from a mid-stage study of its investigational candidate, CT-388, being developed for the treatment of obesity. CT-388 is a once-weekly i ...

Key Takeaways Regeneron will report Q4 results on Jan. 30, with focus on profits from Dupixent and Eylea HD sales.Eylea sales declined due to competition, but strong uptake of Eylea HD may lift total franchise revenues.Dupixent demand across multiple indications likely drove solid profit growth, helping offset Eylea decline.Investors will focus on profits from asthma drug Dupixent and sales of Eylea HD when biotech giant Regeneron Pharmaceuticals, Inc. (REGN) reports fourth-quarter 2025 results on Jan. 30, ...

Core Viewpoint - Momentum investing focuses on "buying high and selling higher," contrasting with traditional strategies of "buying low and selling high" [1] Group 1: Momentum Investing Characteristics - Momentum investing can be risky as stocks may lose momentum when their valuations exceed future growth potential, leading to potential losses for investors [2] - A safer approach involves investing in bargain stocks that exhibit recent price momentum, utilizing tools like the Zacks Momentum Style Score to identify such opportunities [3] Group 2: Rockwell Medical (RMTI) Analysis - Rockwell Medical (RMTI) has shown a significant price increase of 41% over the past four weeks, indicating growing investor interest [4] - RMTI has gained 10.6% over the past 12 weeks, demonstrating its ability to deliver positive returns over a longer timeframe [5] - The stock has a beta of 1.65, suggesting it moves 65% more than the market in either direction, indicating fast-paced momentum [5] - RMTI has a Momentum Score of A, suggesting it is an opportune time to invest in the stock [6] Group 3: Earnings Estimates and Valuation - RMTI has received upward revisions in earnings estimates, earning a Zacks Rank 2 (Buy), which is associated with strong momentum effects [7] - The stock is currently trading at a Price-to-Sales ratio of 0.60, indicating it is reasonably valued at 60 cents for each dollar of sales, suggesting potential for further price appreciation [7] Group 4: Additional Investment Opportunities - Besides RMTI, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, presenting additional investment opportunities [8] - Investors can explore over 45 Zacks Premium Screens tailored to different investing styles to identify potential winning stocks [9]

Key Takeaways RFIL has been witnessing enormous recent price gains as U.S. markets begin 2026 in positive territory.BWMX jumped 32.7% in four weeks, backed by a 44.4% expected earnings growth rate for the current year.KRYS shares rose 10.5% in four weeks as Vyjuvek uptake and EU and Japan approvals support sales growth. U.S. stock markets have started 2026 on a positive note. All three major stock indexes are trading in positive territory. The fourth-quarter 2025 earnings season has been projected to remain ...